[Which biomarkers can we use?].
Gene array testing defined the intrinsic biological subtypes including"luminal A", "luminal B", "HER2-enriched" and "basal" within breast cancer. These subtypes may be approximated using clinicopathological immunochemistry rather than gene expression array criteria. These subtypes have different epidemiological risk factors, different natural histories, and different response to systemic and local therapies. Systemic therapy recommendations follow the subtype classification. "Estrogen receptor", "progesterone receptor", "human epidermal growth factor receptor 2" and "Ki67" are the most important biological markers to classify the subtypes and predict the prognosis and the response to the therapy. The new targeting therapy will require new biomarkers.